Product Information
GABAPENTIN ER 300 MG TABLET is a generic product labeled by ScieGen Pharmaceuticals, Inc., priced at $0.6385 per EA under NDC 50228052390. Its NADAC has been published 39 times since Jan 7, 2026.
FDA first approved this application on Sep 19, 2025. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the gabapentin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
ScieGen Pharmaceuticals, Inc.NDC
50228052390
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GABAPENTINApproval Type
Generic (ANDA)
FDA Application
ANDA218491FDA Approved
9/19/2025
TE Code
AB2
On Market Since
9/20/2025
Pharmacological Classes
Price Statistics
The NADAC for GABAPENTIN ER 300 MG TABLET has been published 39 times since Jan 7, 2026, and over the history we have for it it has declined 56.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6385 per EA |
|---|---|
| All-time high | $1.4921 (Feb 11, 2026) |
| All-time low | $0.6385 (Sep 23, 2026) |
| 52-week high | $1.4921 |
| 52-week low | $0.6385 |
| Median price | $1.2083 |
| Average price | $1.1831 |
| Largest weekly change | -20.4% (Jul 22, 2026) |
| Weeks tracked | 39 |
| Tracking since | Jan 7, 2026 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ScieGen Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
gabapentin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GABAPENTIN ER 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN ER 300 MG TABLET, manufactured by ScieGen Pharmaceuticals, Inc., is $0.6385 per EA (NDC 50228052390), effective Sep 30, 2026.
How has the price of GABAPENTIN ER 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for GABAPENTIN ER 300 MG TABLET has declined 56.6%. It has been tracked across 39 weekly CMS publications since Jan 7, 2026.
What are the highest and lowest recorded NADAC prices for GABAPENTIN ER 300 MG TABLET?
Since Jan 7, 2026, the NADAC for GABAPENTIN ER 300 MG TABLET has ranged from a low of $0.6385 (Sep 23, 2026) to a high of $1.4921 (Feb 11, 2026), with a median of $1.2083 per EA.
Are there cheaper alternatives to GABAPENTIN ER 300 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as GABAPENTIN ER 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures GABAPENTIN ER 300 MG TABLET?
GABAPENTIN ER 300 MG TABLET (NDC 50228052390) is labeled by ScieGen Pharmaceuticals, Inc., and CMS classifies it as a generic product.